What is the equivalent insulin glargine dose when converting from Triseba (insulin lispro protamine) 75 units twice daily?

Dose Conversion from Triseba to Insulin Glargine

When converting from Triseba (insulin lispro protamine) 75 units twice daily (total 150 units/day) to insulin glargine, start with 120 units once daily, which represents 80% of the total daily NPH-like insulin dose.

Conversion Rationale

The FDA label for insulin glargine provides explicit guidance for converting from twice-daily NPH insulin (or NPH-like intermediate-acting insulins) to once-daily insulin glargine: use 80% of the total NPH dosage being discontinued 1. Since Triseba contains 75% insulin lispro protamine suspension (an NPH-like intermediate-acting component), this same conversion principle applies.

Calculation:

• Current Triseba dose: 75 units × 2 = 150 units/day total
• Insulin glargine starting dose: 150 units × 0.80 = 120 units once daily

Key Implementation Points

Timing and monitoring:

• Administer insulin glargine at the same time each day (can be any time, but consistency is critical) 1
• Increase blood glucose monitoring frequency during the transition period 1
• The FDA explicitly warns that dosage adjustments should only be made under medical supervision with appropriate glucose monitoring 1

Expected adjustments:

• This 80% dose reduction is specifically designed to lower hypoglycemia risk during the transition 1
• Further titration will likely be needed based on fasting plasma glucose values
• The ADA guideline recommends increasing by 2 units every 3 days to reach fasting glucose goals without hypoglycemia 2

Critical Caveats

Loss of prandial coverage: Triseba contains 25% rapid-acting insulin lispro, providing some mealtime coverage. Switching to basal-only insulin glargine eliminates this prandial component. Monitor postprandial glucose closely—if A1C remains above goal despite adequate basal control, you will need to add:

• A GLP-1 receptor agonist (preferred per ADA guidelines) 2, or
• Prandial insulin with meals 2

Hypoglycemia risk: The long-acting effect of insulin glargine may delay recovery from hypoglycemia 1. Research shows that while premixed insulins like Triseba have higher overall hypoglycemia rates, they paradoxically have lower nocturnal hypoglycemia rates compared to glargine 3. Monitor for nocturnal hypoglycemia patterns during conversion.

Weight considerations: Expect less weight gain with glargine compared to the premixed regimen (research shows approximately 2.5 kg vs 3.6-6.4 kg weight gain) 3, 4.